+82.7%
IREN vs GSK
+44.5%
+38.2%
-95.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +7.3% | -1.9% | +9.2% | +6.7% |
| 7D | +26.0% | -1.8% | +27.9% | +25.4% |
| 30D | +14.9% | -2.2% | +17.1% | +14.3% |
| 3M | -27.8% | -1.8% | -26.0% | -27.6% |
| 6M | +1.9% | -10.6% | +12.5% | -0.3% |
| YTD | +18.3% | +4.4% | +13.9% | +21.2% |
| 1Y | +71.0% | +30.4% | +40.6% | +82.2% |
| 3Y | +882.0% | +60.1% | +821.9% | +985.3% |
| All | +82.7% | +44.5% | +38.2% | +67.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling